News Archives - Page 2 of 801

MondayJul 27, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology's most persistent development challenges. Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support…

FridayJul 24, 2026 11:15 am

Greenland Mines Ltd. (NASDAQ: GRML) Advances World-Class Palladium Deposit with Major Resource Upgrade

The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian supplier, and persistent demand from the automotive sector creates a clear rationale for Western nations to secure alternative sources of palladium. The latest news from Greenland Mines confirms that its Skaergaard project just became more valuable. The 2026 field season is already underway at Skaergaard, with drilling, bulk sampling for metallurgical test work, geotechnical measurements, engineering studies and environmental baseline all in progress. Palladium is one of the most strategically important metals on earth, and the supply chain that delivers it to Western manufacturers has never been…

FridayJul 24, 2026 10:30 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions. Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair. These developments underscore the company's broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies. Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply…

FridayJul 24, 2026 9:45 am

Wrap Technologies Inc. (NASDAQ: WRAP) Is Building a Modern Public Safety Platform by Integrating Tools, Training and Policy

Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools, training, and policy into one Non-Lethal Response(TM) ecosystem for modern public safety. Its platform pairs the patented BolaWrap(R) 150 remote response-to-resistance device with Wrap Reality(TM) VR training, Wrap Vision(TM) evidence management, and Wrap Tactics(TM) digital training, reinforced by IADLEST-certified instruction and human-centered policy frameworks. In July 2026 the company launched WrapShield(TM), extending that integrated approach from the officer’s belt to an autonomous, AI-enabled platform designed to detect, orchestrate, and respond. A System, not a Single Device Law enforcement officers routinely face non-compliant individuals and people…

FridayJul 24, 2026 9:00 am

Safe Pro Group Inc. (NASDAQ: SPAI) Awarded USAF Contract Focused on Developing New AI Dataset for Airfield Operations

Safe Pro Group recently announced that it was awarded a Small Business Innovation Research (“SBIR”) contract focused on developing a new AI dataset that will be used in airfield operations. Specifically, the dataset will be made using images of debris and damage that are commonly encountered on military and civilian airfields and will help address common challenges that the Department of the Air Force (“DAF”) faces. Developing these AI datasets could rapidly expand the applicability of Safe Pro’s computer vision technology and open up a brand-new potential market opportunity in both commercial and defense airfield operations. Safe Pro Group (NASDAQ:…

ThursdayJul 23, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific…

ThursdayJul 23, 2026 9:45 am

SS Innovations International Inc. (NASDAQ: SSII) to Showcase SSi Mantra Surgical Robotic System at SRS 2026 as Company Expands Global Clinical Footprint

SS Innovations will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting in Florida on July 23-26. The presentation will feature a live kidney telesurgery broadcast from India, demonstrating the remote capabilities of the SSi Mantra platform. Chairman and CEO Dr. Sudhir Srivastava to participate in multiple conference presentations covering telesurgery, robotic surgery adoption and regulatory developments. As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, including cardiac, pediatric and telesurgical procedures. Approximately 2,100 physicians have already been trained on the platform, which has…

ThursdayJul 23, 2026 9:00 am

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Emerges as Viable Solution to Mounting Battlefield GPS Failures

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. The Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict. Sparc AI approaches that problem from the software side rather than through new hardware, offering its Overwatch platform that delivers precision navigation and target acquisition for drones and autonomous systems. The company has also been building the commercial infrastructure to bring that technology to actual defense customers. Modern militaries-built decades of doctrine on the assumption that satellites would always know where a soldier, drone or missile stood,…

WednesdayJul 22, 2026 9:45 am

Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF): Advancing Brazilian Rare Earth Assets as Global Supply Chains Look Beyond China

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising. Canamera has commenced exploration at its São Sepé Project in Brazil, where three high-priority rare earth targets have already been identified The company is building a diversified Brazilian rare earth portfolio as Western nations seek alternatives to China's supply dominance These developments position Canamera to capitalize on growing demand for secure, strategic sources of critical minerals Rare earth elements have become indispensable to the technologies powering the global economy, from electric vehicles and wind turbines to advanced defense systems and consumer electronics. Yet…

WednesdayJul 22, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

The company has received Scientific Advice from Germany's Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program. The regulatory feedback provides early guidance on the company's biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The company's lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting. VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered…

Site Search

Company Search

Category: News